Saniona: Interim study results presented in the Prader-Willi syndrome
Research Note
2018-01-08
15:42
Saniona reported earlier today results from a phase IIa study in Prader-Willi syndrome. The study was subject to interim-analyses in October 2017 since some patients discontinued the study due to adverse effects. Based on the results, a clinically meaningful weight loss as well as a reduction in hyperphagia (food craving) was reported in the study. On the other hand, plasma concentrations of tesofensine were reported to be two to four times higher as compared to previous studies with tesofensine. This may explain the high dropout and adverse effects in the study.
AH
Anders Hedlund
Disclosures and disclaimers